UNIVERSITY OF WASHINGTON

Sarah Psutka discusses the expanded access program for cretostimogene in BCG-unresponsive bladder cancer, highlighting its 74% complete response rate and strong durability. The EAP aims to gather real-world data from diverse patient populations, addressing access issues and collecting prospective data on safety, efficacy, and patient-reported outcomes.

The Phase III AALL1731 trial showed Blincyto (blinatumomab) significantly improved three-year disease-free survival (DFS) in pediatric patients with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) when added to chemotherapy, with a 61% decrease in relapse risk. The trial's interim analysis led to early termination due to the observed benefit, highlighting Blincyto's potential as a transformative treatment in this patient population.

The 2024 Nobel Prize in Chemistry recognizes AI's transformative impact on protein science, awarding Demis Hassabis and John Jumper for AlphaFold2 and David Baker for computational protein design. AlphaFold2 predicts protein structures with near-experimental accuracy, revolutionizing drug development and biomedical research. Baker's Rosetta algorithm designs new proteins from scratch, opening possibilities for new medical treatments and nanotechnology. This marks the first Nobel prize for an AI-enabled scientific breakthrough, highlighting AI's potential across scientific fields and its role in accelerating drug discovery and personalized medicine.

Santiago, diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), participated in a clinical trial combining chemotherapy with blinatumomab, showing a 61% reduction in relapse risk. The study, published in the New England Journal of Medicine, indicates blinatumomab significantly improves disease-free survival, potentially becoming the new standard of care for B-ALL patients.

A clinical trial combining standard chemotherapy with blinatumomab for newly diagnosed B-ALL in children showed a 61% reduction in relapse or death risk, significantly improving disease-free survival rates, marking a new standard of care in childhood cancer treatment.

Adding blinatumomab to chemotherapy significantly improved 3-year disease-free survival (DFS) rates in pediatric patients with standard-risk B-ALL, reducing bone marrow relapse rates. The study, AALL1731, showed DFS rates of 96% with blinatumomab plus chemotherapy vs 87.9% with chemotherapy alone. Safety profiles were manageable, with no deaths attributed to blinatumomab.

Blinatumomab added to chemotherapy significantly improves 3-year disease-free survival in children with B-cell acute lymphoblastic leukemia, reducing the hazard ratio for disease recurrence by 61%.

Adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk B-cell acute lymphoblastic leukemia (B-ALL), with a 3-year DFS of 96%.

Adding BLINCYTO to chemotherapy significantly improves disease-free survival in pediatric patients with B-cell acute lymphoblastic leukemia, with a 3-year DFS of 96% compared to 87.9% with chemotherapy alone.

Blinatumomab with chemotherapy significantly improved disease-free survival in pediatric patients with newly diagnosed standard risk B-cell acute lymphoblastic leukemia, according to the phase 3 AALL1731 trial. The 3-year DFS was 96.0% ± 1.2% for blinatumomab arms vs. 87.9% ± 2.1% for chemotherapy alone, with significant reduction in bone marrow relapses and well-tolerated side effects.